Citations

Mayo Clinic

Showing 10 of 108572 citations.

All that hemolyzes with complement is not cold agglutinin syndrome
Jacobs, Jeremy W. , Adkins, Brian D. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Booth, Garrett S.

Revista Paulista de Pediatria | December 18, 2023 | Volume: 42 | Issue: No issue available | Pages: No page available

10.1590/1984-0462/2024/42/2023144 | PMID 38126441 Get It

A pooled patient‐reported outcomes analysis of moderately hypofractionated proton beam therapy and photon‐based intensity modulated radiation therapy for low‐ or intermediate‐risk prostate cancer
Lukez, Alexander , Stish, Bradley J. , Hallman, M.A. , Horwitz, Eric M. , Vapiwala, Neha , Wong, J.K. , Davis, Brian J. , Wong, Jessica Karen , Handorf, Elizabeth A. , Mendenhall, Nancy P. , Henderson, Randal H.

The Prostate | December 18, 2023 | Volume: 84 | Issue: 4 | Pages: 395-402

10.1002/pros.24660 | PMID 38108113 Get It

AbstractBackgroundWe sought to characterize and compare late patient‐reported outcomes (PROs) after moderately hypofractionated intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) for localized prostate cancer (PC).MethodsThis multi‐institutional analysis included low‐ or intermediate‐risk group PC patients treated with moderately hypofractionated radiation to an intact prostate stratified by treatment modality: IMRT or PBT. The primary outcomes were prospectively collected patient‐reported late gastrointestinal (GI) and genitourinary (GU) toxicity assessed by International Prostate Symptom Score (IPSS) and Expanded PC Index Composite (EPIC). Multivariable regression analysis (MVA) controlling for age, race, and risk group tested the effect of time, treatment, and their interaction.Results287 IMRT and 485 PBT patients were included. Intermediate risk group (81.2 vs. 68.2%; p < 0.001) and median age at diagnosis (70 vs. 67 years; p < 0.001) were higher in the IMRT group. On MVA, there was no significant difference between modalities. PBT IPSS did not differ from IMRT IPSS at 12 months (odds ratio [OR], 1.19; p = 0.08) or 24 months (OR, 0.99; p = 0.94). PBT EPIC overall GI function at 12 months (OR, 3.68; p = 0.085) and 24 months (OR 2.78; p = 0.26) did not differ from IMRT EPIC overall GI function. At 24 months, urinary frequency was no different between PBT and IMRT groups (OR 0.35; p = 0.096).ConclusionsThis multi‐institutional analysis of low‐ or intermediate‐risk PC treated with moderately hypofractionated PBT and IMRT demonstrated low rates of late patient‐reported GI and GU toxicities. After covariate adjustment, late GI and GU PROs were not significantly different between PBT or IMRT cohorts.
The Effects of Protein and Carbohydrate Supplementation, with and without Creatine, on Occupational Performance in Firefighters
Elstad, Kaia, Malone, Conley, Luedke, Joel, Jaime, Salvador J., Dobbs, Ward C. , Kerksick, Chad M. , Markert, Adam, Jagim, Andrew R. , Kerksick, Chad M , Jagim, Andrew R , Almonroeder, Thomas Gus

Nutrients | December 18, 2023 | Volume: 15 | Issue: 24 | Pages: 5134

10.3390/nu15245134 | PMID 38140393 Get It

Background: The purpose of this study was to assess the effects of protein and carbohydrate supplementation, with and without creatine, on occupational performance in firefighters. Methods: Using a randomized, double-blind approach, thirty male firefighters (age: 34.4 ± 8.4 yrs., height: 1.82 ± 0.07 m; weight: 88.6 ± 12.5 kg; BF%: 17.2 ± 5.8%) were randomized to receive either (A.) 25 g of whey protein isolate + 25 g of carbohydrate powder (ProCarb group); or (B.) ProCarb + 5 g of creatine (Creatine group) in a double-blind fashion over a period of 21–26 days (depending on shift rotations) to evaluate the impact of supplementation on occupation-specific performance. At baseline and following supplementation, firefighters completed a battery of tests. These tests included an aerobic speed test on an air-braked cycle ergometer followed by the hose carry, body drag, stair climb, and Keiser sled hammer for time. Results: No significant differences in measures of performance were observed at baseline (p > 0.05). There was a significant main effect for time observed for rescue, stair climb, total time to completion, and time trial performance (p < 0.05). There was a significant group × time (p < 0.05) interaction for rescue and forcible entry. Independent sample t-tests indicated that the Creatine group experienced a greater reduction (from baseline) in completion time for the rescue (1.78 ± 0.57 s, 95% CI: 0.61, 2.95 s, p = 0.004) and forcible entry (2.66 ± 0.97 s, 95% CI: 0.68, 4.65 s, p = 0.01) tests compared to the ProCarb group. No significant group × time interactions were observed for the hose line advance, stair climb, total time to completion, and time trial performance (p > 0.05). Conclusions: The addition of supplemental creatine to a protein and carbohydrate supplement to the diet of career firefighters throughout a three week period improves occupational performance in firefighters in specific areas of high-intensity, repetitive actions.
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Rencsok, Emily M. , Slopen, Natalie , McManus, Hannah D. , Autio, Karen A. , Morgans, Alicia K. , McSwain, Lawrence, Barata, Pedro C. , Cheng, Heather H. , Dreicer, Robert , Gerke, Travis , Green, Rebecca , Heath, Elisabeth I. , McKay, Rana R. , Nowak, Joel , Pileggi, Shannon , Pomerantz, Mark M., Whang, Young E. , Ragin, Camille , Vinson, Jake , Villanti, Paul , Haneuse, Sebastien , Mucci, Lorelei A. , George, Daniel J. , Registry, for the IRONMAN, Barata, Pedro , Howard, Lauren E , McKay, Rana R , Nowak, Joel , Pileggi, Shannon , Pomerantz, Mark M , Rathkopf, Dana E , Tagawa, Scott T , Whang, Young E , Ragin, Camille , Odedina, Folakemi , Kantoff, Philip W , Vinson, Jake , Villanti, Paul , Haneuse, Sebastien , Mucci, Lorelei A , George, Daniel J , Cheng, Heather H , Morgans, Alicia K , Dreicer, Robert , Howard, Lauren E. , Tagawa, Scott T. , Kantoff, Philip W. , Registry, for the IRONMAN

Cancer Research Communications | December 18, 2023 | Volume: 4 | Issue: 1 | Pages: 55-64

10.1158/2767-9764.crc-23-0446 | PMID 38108490 Get It

Abstract Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the association between baseline and longitudinal pain and mortality. This is a prospective cohort study of individuals with newly diagnosed advanced prostate cancer enrolled in the International Registry for Men with Advanced Prostate Cancer (IRONMAN) from 2017 to 2023 at U.S. sites. Differences in four pain scores at study enrollment by race were investigated. Cox proportional hazards models and joint longitudinal survival models were fit for each of the scale scores to estimate HRs and 95% confidence intervals (CI) for the association with all-cause mortality. The cohort included 879 individuals (20% self-identifying as Black) enrolled at 38 U.S. sites. Black participants had worse pain at baseline compared with White participants, most notably a higher average pain rating (mean 3.1 vs. 2.2 on a 10-point scale). For each pain scale, higher pain was associated with higher mortality after adjusting for measures of disease burden, particularly for severe bone pain compared with no pain (HR, 2.47; 95% CI: 1.44–4.22). The association between pain and all-cause mortality was stronger for participants with castration-resistant prostate cancer compared with those with metastatic hormone-sensitive prostate cancer and was similar among Black and White participants. Overall, Black participants reported worse pain than White participants, and more severe pain was associated with higher mortality independent of clinical covariates for all pain scales. Significance: Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population are needed to determine the factors upon which to intervene to improve quality of life and survivorship, particularly for Black individuals.
Limitations in Evaluating Machine Learning Models for Imbalanced Binary Outcome Classification in Spine Surgery: A Systematic Review
Ghanem, Marc , Ghaith, Abdul Karim , El-Hajj, Victor Gabriel , Bhandarkar, Archis R. , Giorgio, Andrea de , Elmi‐Terander, Adrian , Bydon, Mohamad , Bhandarkar, Archis, de Giorgio, Andrea , Ghaith, Abdul Karim , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel

Brain Sciences | December 18, 2023 | Volume: 13 | Issue: 12 | Pages: 1723

10.3390/brainsci13121723 | PMID 38137171 Get It

Clinical prediction models for spine surgery applications are on the rise, with an increasing reliance on machine learning (ML) and deep learning (DL). Many of the predicted outcomes are uncommon; therefore, to ensure the models’ effectiveness in clinical practice it is crucial to properly evaluate them. This systematic review aims to identify and evaluate current research-based ML and DL models applied for spine surgery, specifically those predicting binary outcomes with a focus on their evaluation metrics. Overall, 60 papers were included, and the findings were reported according to the PRISMA guidelines. A total of 13 papers focused on lengths of stay (LOS), 12 on readmissions, 12 on non-home discharge, 6 on mortality, and 5 on reoperations. The target outcomes exhibited data imbalances ranging from 0.44% to 42.4%. A total of 59 papers reported the model’s area under the receiver operating characteristic (AUROC), 28 mentioned accuracies, 33 provided sensitivity, 29 discussed specificity, 28 addressed positive predictive value (PPV), 24 included the negative predictive value (NPV), 25 indicated the Brier score with 10 providing a null model Brier, and 8 detailed the F1 score. Additionally, data visualization varied among the included papers. This review discusses the use of appropriate evaluation schemes in ML and identifies several common errors and potential bias sources in the literature. Embracing these recommendations as the field advances may facilitate the integration of reliable and effective ML models in clinical settings.
Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia
Gupta, Supriya , Kohorst, Mira A. , Kohorst, Mira , Alkhateeb, Hassan B , Alkhateeb, Hassan B.

European Journal of Haematology | December 18, 2023 | Volume: 112 | Issue: 1 | Pages: 51-63

10.1111/ejh.14132 | PMID 38105391 Get It

AbstractRelapsed and refractory B‐cell acute lymphoblastic leukemia (B‐ALL) is an aggressive B‐cell neoplasm associated with poor outcomes. Conventional multiagent chemotherapy and bispecific antibody therapy may induce remission; however, relapse rates remain high and overall survival is poor. Chimeric antigen receptor T‐cell (CAR‐T) therapy provides durable, deep complete remission, and long‐term cures in relapsed and refractory B‐ALL. However, with this new treatment modality, 10%–30% of patients do not achieve remission, and over 50% experience relapse after therapy. Currently, there are two approved CD19‐specific CAR‐T cell constructs in B‐ALL, Tisagenlecleucel and Brexucabtagene Autoleucel by the United States Food and Drug Administration, and the European Medicines Agency (EMA). In this review, we discuss patients, disease, and CAR‐T predictors of outcomes in B‐ALL. We describe the two approved CD19‐directed CAR‐T cell products, review the current literature, and discuss factors associated with high risks of therapy failure and future direction in CAR‐T cell therapy for B‐ALL.
Large mandibular mass with several floating teeth: granular cell ameloblastoma
Razmi, Samuel E. , Hayden, Richard E. , Razmi, Samuel , Chang, Brent A.

Journal of Surgical Case Reports | December 18, 2023 | Volume: 2023 | Issue: 12 | Pages: No page available

10.1093/jscr/rjad666 | PMID 38111489 Get It

Abstract Ameloblastomas are benign, locally aggressive, odontogenic epithelial neoplasms. We present a patient with a rare granular cell ameloblastoma. This is a case report and literature review conducted from July 2022 to the present. Our 52-year-old male patient presented to the clinic with a several month history of right lower lateral lip swelling and dental complaints. On imaging and physical exam, we noticed a large heterogenous, multiloculated, expansile lesion of the right mandible with several floating teeth. After incisional biopsy confirmed multicystic granular cell ameloblastoma, the patient underwent successful surgical resection and osteocutaneous fibula free-flap reconstruction. At the time of writing this report, 7 years after resection, the patient is alive with no evidence of recurrence. The recognition and treatment of mandibular lesions can represent significant clinical challenges, especially for rarely seen subtypes such as the granular cell ameloblastoma. Special consideration must be given for the identification and treatment of these neoplasms.
Clinfo.ai: An Open-Source Retrieval-Augmented Large Language Model System for Answering Medical Questions using Scientific Literature
Lozano, Alejandro , Fleming, Scott L. , Chiang, Chia‐Chun , Shah, Nigam H. , Lozano, Alejandro

Biocomputing 2024 | December 18, 2023 | Volume: No volume available | Issue: No issue available | Pages: 8-23

10.1142/9789811286421_0002 Get It

Embolization of arteriovenous malformations of head and neck: A systematic review
Malik, Muhammad Hammad , Jabal, Mohamed Sobhi , Kobeissi, Hassan , Gupta, Rishabh , Bilgin, Cem , Brinjikji, Waleed , Kobeissi, Hassan , Bilgin, Cem

Interventional Neuroradiology | December 17, 2023 | Volume: 31 | Issue: 6 | Pages: 852-858

10.1177/15910199231219823 | PMID 38105437 Get It

Background Cervicofacial arteriovenous malformations (AVMs) are a significant source of morbidity. Endovascular embolization has emerged as a promising treatment technique for these lesions. However, current literature on cervicofacial AVM embolization mostly consists of single-agent oriented case series, and to date, no comprehensive study has compared the outcomes of available embolic agents. Purpose To investigate the performance of different embolic agents in the management of cervicofacial AVMs. Methods We systematically searched Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials Scopus, and Web of Science. Studies providing data for the endovascular treatment of cervicofacial AVMs were included. The data regarding complication and cure rates were collected for each embolic agent. Pooled event rates were presented as descriptive statistics. Results Eleven studies comprising 204 patients were included in the review. The overall complete and partial cure rates were 62.2% (127/204) and 36.2% (74/204), respectively. Embolization failed to achieve significant improvement in only 1.6% (3/204) of the patients. The complete cure rates were 87.5% (75–100%) for n-Butyl cyanoacrylate (NBCA, glue), 80.5% (61–100%) for Onyx (Medtronic, MN, USA), and 51.5% (18–85%) for ethanol. The overall complication rate was 30% (61/204). The complication rates were 33% (12.5–53%) for ethanol, 14% (0–28%) for Onyx, and 0% for NBCA. Conclusions Our systematic review supports that endovascular embolization is an effective treatment option for cervicofacial AVMs. In our review, the use of Onyx and NBCA was associated with consistently high complete cure rates and a promising safety profile. However, more research is needed to investigate the use of different embolic agents in the treatment of cervicofacial AVMs.
Profession-based manual therapy nomenclature: exploring history, limitations, and opportunities
Jacobson, Eric, Fritz, Sandy, Mettler, Paul, Kettner, Norman W. , Franklin, G. , Hensel, Kendi , Lesondak, David , Consorti, Giacomo , Frank, L, Křemen, Václav , Martin, C., Landels, Bernie, Standley, Paul R., Kremen, Vaclav , Degenhardt, Brian F. , Dun, Patrick L.S. van , Mettler, Paul, Frank, Leah, Reed, William R , MacDonald, Cameron W. , Martin, Crystal

Journal of Manual & Manipulative Therapy | December 17, 2023 | Volume: 32 | Issue: 1 | Pages: 96-110

10.1080/10669817.2023.2288495 | PMID 38104312 Get It